Abstract 4367109: Evaluation of a Novel Artificial Intelligence Electrocardiogram Tool for Early Identification of Pulmonary Arterial Hypertension and Chronic Thromboembolic Pulmonary Hypertension

Introduction: Pulmonary hypertension (PH) is a life-threatening, progressive disease with non-specific symptoms, often leading to delayed diagnosis. Early identification of World Health Organization Group 1 (Pulmonary Arterial Hypertension, PAH) and Group 4 (Chronic Thromboembolic Pulmonary Hypertension, CTEPH) is essential, as effective therapies can improve outcomes. Hypothesis: An electrocardiogram-based AI algorithm for PH detection (ECG-AI PH) may enable earlier diagnosis and reduce healthcare utilization, including hospitalizations and procedures. Methods: Retrospective analysis used a de-identified data platform of >7M clinical records from a multistate integrated health system. Adult precapillary PH patients (mPAP >20 mmHg, PVR >2 WU, PCWP ≤15 mmHg) were identified as PAH or CTEPH based on ICD codes, use of approved therapies, or surgical interventions (for CTEPH) between 2002 and 2024. ECG-AI PH was applied to ECGs within 30 days of diagnostic right heart catheterization, using a 5:1 randomly sampled PH-negative control cohort. Training set patients were excluded. Clinical event frequency was compared between two intervals: from first possible PH symptom (dyspnea, syncope, chest pain, fatigue, lower limb swelling) to diagnosis, and from symptom onset to first positive ECG-AI PH prediction. Results: A total of 1882 PAH and 359 CTEPH patients met inclusion criteria. Of these, 1340 PAH and 258 CTEPH patients had symptom codes prior to diagnosis. Both groups showed prolonged intervals from symptom onset to diagnosis, with multiple diagnostic procedures and hospitalizations (Figure). ECG-AI PH performance evaluation on the test set included 647 PAH and 152 CTEPH patients. ECG-AI PH achieved AUCs of 0.90 and 0.89 for PAH and CTEPH, sensitivities of 80.3% and 76.8%, and specificities of 83.4% and 82.4%. Among those tested, 576 PAH and 95 CTEPH patients had a positive ECG-AI PH prediction after symptom onset but before diagnosis. Compared to the current patient journey, the interval between initial symptoms and a positive output from ECG-AI PH was shorter and had fewer diagnostic tests/visits. Conclusion: ECG-AI PH demonstrated strong performance in detecting PAH and CTEPH. It may reduce diagnostic delays, support earlier PH-focused screening (e.g., echocardiograms evaluating the right heart), enable earlier intervention, and reduce pre-diagnosis healthcare burden, benefitting both patient outcomes and healthcare system efficiency.